Gujarat Magazine

Tendonitis Treatment Market Size in the 7MM is projected to experience growth during the Study Period (2020-2034)

 Breaking News
  • No posts were found

Tendonitis Treatment Market Size in the 7MM is projected to experience growth during the Study Period (2020-2034)

September 16
12:32 2024
Tendonitis Treatment Market Size in the 7MM is projected to experience growth during the Study Period (2020-2034)

“Tendonitis Therapies such as TENDAXION, TENDOFIT, ZEPTIDE, TENACTIVE/TENDOACTIVE, TENDOMAC, RITISAL, and others”

 

The Tendonitis Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for o Tendonitis therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence

 

DelveInsight’s “Tendonitis Drugs Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of the Tendonitis, historical and forecasted epidemiology as well as the Tendonitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Unlock detailed insights into the Tendonitis Market by downloading the comprehensive report from DelveInsight @ Tendonitis Therapeutics Market

 

Key Takeaways from the Tendonitis Market Report

  • The Growth of the Tendonitis Market is expected to be primarily driven by an expanding patient population, and advancement in diagnostic methods.
  • The leading Tendonitis Companies such as MiMedex Group Inc, MEDRx USA Inc, Cerimon Pharmaceuticals, InGeneron Inc, ZetrOZ Inc, ZARS Pharma Inc, Smith & Nephew Inc., and others.
  • Promising Tendonitis Therapies such as TENDAXION, TENDOFIT, ZEPTIDE, TENACTIVE/TENDOACTIVE, TENDOMAC, RITISAL, and others
  • As per the DelveInsight estimates, the total Tendinopathy Gender-specific cases in the United States was ~8,499,400 and 3,642,600 cases for males and females, respectively in 2022, which are expected to grow during the study period, i.e., 2019–2032.
  • In August 2024:- Wrightington, Wigan and Leigh NHS Foundation Trust- A Prospective, Double Blind, Single Centre, RCT, Comparing the Effectiveness of Physiotherapy in Addition to One of 3 Types of Image Guided Injection of the Common Extensor Tendon, on Pain and Function in Patients With Tennis Elbow.

 

Gain a competitive edge in the Tendonitis Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Tendonitis Treatment Drugs

 

Tendonitis Epidemiology Segmentation in the 7MM

• Total Tendonitis Incident Cases

• Tendonitis Type-specific Incident Cases

• Total Tendonitis Treated Cases

• Tendonitis Region-specific Incident Cases

• Tendonitis Gender-specific Incident Cases

 

Tendinopathy Treatment Market Landscape

The treatment landscape for tendinopathy is rapidly evolving, with numerous companies actively developing new therapies. Around 40-50% of patients currently undergo physiotherapy as part of their treatment. Recently, there’s been a surge in nutraceutical products that appear to support the healing of tendon injuries and may also serve as preventive measures. Although preclinical results are promising, the available literature on this topic remains limited. Managing tendinopathy with oral supplements is still a relatively new approach.

 

Tendinopathy Market Insights

Tendinopathy refers to a complex and multifaceted condition of the tendon, marked by pain, diminished function, and decreased exercise tolerance. The most frequently affected tendons due to overuse include the rotator cuff, medial and lateral elbow epicondyles, patellar, gluteal, and Achilles tendons. Key histological and molecular characteristics of tendinopathy include collagen fiber disorganization, increased microvasculature and sensory nerve innervation, disrupted extracellular matrix homeostasis, elevated immune cell activity and inflammatory mediators, and heightened cellular apoptosis.

 

Discover key developments and opportunities in the Tendonitis Market. Click here to learn more from DelveInsight’s latest report @ Tendonitis Market Size

 

Tendonitis Emerging Drugs

  • SI-613: Seikagaku Corporation

SI-613 is a formulation in which hyaluronic acid and a non-steroidal anti-inflammatory drug (NSAID) are chemically bound using Seikagaku’s own proprietary technology. SI-613 was designed to provide pain relief and anti-inflammatory effect by sustained release of NSAID, and the joint function improving effect by hyaluronic acid. It is expected to provide prompt and sustained relief of the severe pain and inflammation associated with osteoarthritis and enthesopathy. The drug is currently in phase II of clinical trials for the treatment of Tendonitis.

  • MP1032: MetrioPharm

MP1032’s mode of action – to accelerate the healing process – allows for the use of MP1032 as a therapeutic for Tendonitis before a tendinosis develops. In addition, MP1032 could accelerate the repair of already damaged tendons and thus also shorten the duration of tendinosis treatments. The drug is currently in phase I of clinical trials for the treatment of Tendonitis.

 

Tendinopathy Drugs and Companies

  • OCS-05 IV administration: Oculis
  •  BAT4406F Injection: Bio-Thera Solutions
  • Ravulizumab: Alexion Pharmaceuticals
  • B001: Shanghai Drug Research Development Co. Ltd.
  • Inebilizumab: Hansoh BioMedical R&D Company

 

Tendinopathy Market Dynamics

The dynamics of the Tendinopathy market are expected to evolve in the coming years. Preclinical models have supported this emerging therapeutic approach, but there is a notable lack of clinical studies involving stem cells for enhancing tendon repair or treating Tendinopathy, especially when compared to scaffolds and growth factors.

 

Download DelveInsight’s Tendonitis Market report today and stay ahead in this rapidly evolving field. @ Tendonitis Clinical Trials

 

Scope of the Tendonitis Market Report

  • Coverage- 7MM
  • Tendonitis Companies- MiMedex Group Inc, MEDRx USA Inc, Cerimon Pharmaceuticals, InGeneron Inc, ZetrOZ Inc, ZARS Pharma Inc, Smith & Nephew Inc., and others.
  • Tendonitis Therapies- TENDAXION, TENDOFIT, ZEPTIDE, TENACTIVE/TENDOACTIVE, TENDOMAC, RITISAL, and others
  • Tendonitis Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Tendonitis Unmet Needs, KOL’s views, Analyst’s views, Tendonitis Market Access and Reimbursement

 

Download the report to understand which factors are driving Tendonitis market trends @ Tendonitis Market Trends

 

Table of Content

1. Key Insights

2. Executive Summary of Tendonitis

3. Competitive Intelligence Analysis for Tendonitis

4. Tendonitis: Market Overview at a Glance

5. Tendonitis: Disease Background and Overview

6. Patient Journey

7. Tendonitis Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Tendonitis Treatment

11. Marketed Products

12. Emerging Therapies

13. Tendonitis: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Tendonitis

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/